SCHEMBL2856801

SCHEMBL2856801

CN1CCCN(S(=O)(=O)c2cccc(C(N)=O)c2)CC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.76
POLB P06746 1/20 0.68
LMNA P02545 4/20 0.65
ALDH1A1 P00352 2/20 0.65
MAPK1 P28482 1/20 0.63
APOBEC3A P31941 1/20 0.60
APOBEC3G Q9HC16 1/20 0.60
TSHR P16473 1/20 0.60
HTT P42858 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
AKR1C3 P42330 1/20 0.59
MAPT P10636 2/20 0.59
IL1RN P18510 1/20 0.59
PKM P14618 1/20 0.57
NPC1 O15118 1/20 0.57
USP2 O75604 1/20 0.56
ALOX15 P16050 1/20 0.56
HSD17B10 Q99714 1/20 0.56
KDM1A O60341 1/20 0.56
PABPC1 P11940 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2852725 0.95 GAA (0.74) GAAPOLBLMNAALDH1A1MAPK1
SCHEMBL5039031 0.88 GAA (0.97) GAAPOLBLMNAALDH1A1TSHR
SCHEMBL14507610 0.86 GAA (1.00) GAALMNAALDH1A1TSHRHTT
SCHEMBL3824747 0.82 MAPT (0.76) GAAPOLBLMNAALDH1A1MAPK1
SCHEMBL3658812 0.82 NPC1 (0.73) GAAPOLBLMNAALDH1A1MAPK1
SCHEMBL30695442 0.82 MAPT (0.76) GAAPOLBLMNAALDH1A1MAPK1
Hydrochloric Acid SCHEMBL4254371 0.81 MAPT (0.74) GAAPOLBLMNAALDH1A1MAPK1
SCHEMBL2856804 0.81 APOBEC3A (0.67) GAAPOLBLMNAMAPK1APOBEC3A
SCHEMBL14696991 0.81 POLB (0.69) GAAPOLBLMNAMAPK1APOBEC3A
Hydrochloric Acid SCHEMBL4254478 0.80 GAA (0.63) GAAPOLBLMNAMAPK1APOBEC3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 GAA 4722/4885POLB 4035/4885LMNA 3896/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 GAA 4722/4885POLB 4035/4885LMNA 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.